Study of cefadroxil effectiveness in adult patients with Staphylococcus aureus bloodstream infection

2 1 1 1

What is this study about?

This study focuses on Staphylococcus aureus bacteremia, which is a serious blood infection caused by bacteria called Staphylococcus aureus. The study will investigate how the antibiotic cefadroxil works in treating this type of infection. This medication belongs to a group of antibiotics that are taken by mouth in the form of hard capsules.

The purpose of this research is to understand how the body processes and responds to cefadroxil in patients who have a bloodstream infection. The study will examine how the medication moves through the body and how effective it is at fighting the infection. Participants will receive cefadroxil capsules for up to 6 months, with a maximum daily dose of 4 grams.

During the study, researchers will monitor how well the treatment works and watch for any side effects that may occur. The medication will only be given to patients whose infection has already shown improvement with initial treatment and who can take medications by mouth. This research will help determine the most appropriate dosing of cefadroxil for treating this type of infection.

1 Initial assessment

After being diagnosed with Staphylococcus aureus bloodstream infection, your eligibility for the study will be evaluated

Your current treatment with intravenous antibiotics must show improvement

Blood tests must confirm that the infection is no longer present in your blood

2 Medication transition

You will begin taking Cefadroxil Sandoz in the form of hard capsules

The capsules are taken by mouth

This transition must occur within 7 days of your first negative blood culture

3 Treatment monitoring

Your blood levels of the antibiotic will be measured to ensure proper dosing

Medical staff will monitor your response to the treatment

Any side effects or adverse reactions will be recorded

4 Follow-up period

Your progress will be monitored for 90 days

The medical team will check for any signs of infection return

Any hospital readmissions or changes in your condition will be documented

5 Study completion

The study will evaluate if the treatment was successful

Success is measured by: no return of infection, no need to change antibiotics, and no complications related to the infection

Your participation will end after the 90-day monitoring period

Who Can Join the Study?

Must be 18 years or older
Must be able to understand and provide informed consent to participate in the study
Must have a confirmed Staphylococcus aureus bloodstream infection (diagnosed through blood tests and showing signs of infection)
Must show improvement in condition after receiving initial antibiotics through an IV
Must have at least one negative blood test showing the infection is clearing
Must be able to swallow and properly absorb oral medications (no problems with digestion or absorption of medicines)
Must be within 7 days of first negative blood culture result

Who Cannot Join the Study?

Age below 18 years or above 65 years
Known allergy or hypersensitivity to cefadroxil or other similar antibiotics
Pregnant or breastfeeding women
Severe kidney problems (as this may affect how the body processes the antibiotic)
Current participation in other clinical trials
History of serious adverse reactions to antibiotics
Presence of other serious infections besides Staphylococcus aureus in the blood
Severe liver disease
Compromised immune system
Taking medications that could interact with cefadroxil
Unable to provide informed consent
History of seizures or neurological disorders
Severe heart conditions
Active cancer treatment

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Vrije Universiteit Brussel	Jette	Belgium

Trial status

Country	Status	Recruitment Start
Belgium	Recruiting	01.11.2025

Trial locations

Cefadroxil is an antibiotic medication that belongs to the cephalosporin family of antibiotics. It is used to treat bacterial infections, specifically in this case to treat bloodstream infections caused by Staphylococcus aureus bacteria. The medication works by stopping the growth of bacteria by preventing them from building their cell walls. It is typically taken orally and helps the body fight off the infection by eliminating the harmful bacteria from the bloodstream.

Staphylococcus aureus bacteremia – A bloodstream infection caused by the bacteria Staphylococcus aureus, which enters and spreads through the blood. The condition occurs when these bacteria, commonly found on the skin, enter the bloodstream through wounds, medical devices, or other routes. The infection can cause fever, chills, and general weakness. The bacteria can multiply rapidly in the bloodstream, leading to the body’s inflammatory response. Over time, if present in the bloodstream, the bacteria may spread to different parts of the body.

Trial ID:

2025-522547-17-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of cefadroxil effectiveness in adult patients with Staphylococcus aureus bloodstream infection

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?